Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Tonix Pharmaceuticals presented retrospective real-world claims data at the 2026 ASCP Annual Meeting, highlighting that over 40% of fibromyalgia patients in the U.S. are prescribed opioids despite clinical guidelines discouraging their use. The study, based on 261,776 patients from Symphony Health data, underscores the persistent health burden of opioid reliance and the gap in prescriber education regarding non-opioid alternatives.
Key figures
- Mean patient age
- 52.3
- Study cohort size
- 261776
- Female patient percentage
- 92.1%
- Tramadol claim share medicaid
- 11.1%
- Oxycodone claim share medicaid
- 15.7%
- Tramadol claim share commercial
- 13.7%
- Oxycodone claim share commercial
- 13.1%
- Opioid prescription rate medicaid
- 38.8%
- Opioid prescription rate commercial
- 40.2%
- Concomitant opioid benzo rate medicaid
- 20.4%
- Concomitant opioid benzo rate commercial
- 19.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.